GlassScriptPhysician profile
Meredith Walker Oliver
NPI 1770082463
$12,698.24
in general payments reported to CMS, 2019-2025
32 companies · $3,027 in 2025
The $3,027 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,382 · 2022: $1,697 · 2023: $2,504 · 2024: $3,088 · 2025: $3,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,483 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,482.63 |
| Education | $136.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,784.74 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,960.94 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,273.62 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,009.00 | 2021-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $750.66 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $525.25 | 2021-2024 | Linzess |
| Pfizer INC. | $480.32 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $397.83 | 2021-2025 | Givlaari |
| Lilly USA, LLC | $377.93 | 2023-2025 | Omvoh |
| Genzyme Corporation | $377.11 | 2022-2025 | |
| Daiichi Sankyo INC. | $310.41 | 2021-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $306.52 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $272.95 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $263.09 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $190.11 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $189.30 | 2021-2024 | Zeposia |
| Vivus LLC | $182.51 | 2023-2025 | Pancreaze, Qsymia |
| Merck Sharp & Dohme LLC | $148.16 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $109.15 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $108.16 | 2021-2024 | Suflave, Sutab |
| Redhill Biopharma INC. | $87.92 | 2021-2023 | Talicia |
| Phathom Pharmaceuticals, INC. | $87.50 | 2023-2025 | Voquezna |
| Evoke Pharma, INC. | $80.34 | 2021-2025 | |
| Celltrion USA INC. | $70.58 | 2024-2025 | Zymfentra, Vegzelma |
| Ferring Pharmaceuticals INC. | $64.43 | 2022-2023 | Rebyota |
| Fresenius Kabi USA, LLC | $56.48 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $45.91 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $44.47 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $42.55 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.49 | 2024 | Cyltezo |
| W. L. Gore & Associates, INC. | $34.27 | 2022-2023 | Gore Cardioform Septal Occluder |
| Organon LLC | $25.54 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.